Unknown

Dataset Information

TP53 mutations confer resistance to hypomethylating agents and BCL-2 inhibition in myeloid neoplasms.


ABSTRACT:

SUBMITTER: Schimmer RR 

PROVIDER: S-EPMC9198927 | biostudies-literature | 2022 Jun

REPOSITORIES: biostudies-literature